المؤلفون: Bychkov, D. (Dmitrii), Linder, N. (Nina), Tiulpin, A. (Aleksei), Kücükel, H. (Hakan), Lundin, M. (Mikael), Nordling, S. (Stig), Sihto, H. (Harri), Isola, J. (Jorma), Lehtimäki, T. (Tiina), Kellokumpu-Lehtinen, P.-L. (Pirkko-Liisa), von Smitten, K. (Karl), Joensuu, H. (Heikki), Lundin, J. (Johan)

المساهمون: Helsinki Institute for Information Technology, Institute for Molecular Medicine Finland, University of Helsinki, Digital Precision Cancer Medicine (iCAN), Medicum, Johan Edvard Lundin / Principal Investigator, Department of Pathology, Department of Diagnostics and Therapeutics, Clinicum, Department of Surgery, Research Programs Unit, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center, Department of Oncology, Helsinki University Hospital Area, HUS Medical Imaging Center, Tampere University, BioMediTech, Clinical Medicine

المصدر: Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)

مصطلحات موضوعية: Adult, Receptor, ErbB-2, Science, 3122 Cancers, Breast Neoplasms, Biomarkers, Pharmacological, Disease-Free Survival, Article, Cohort Studies, Tumour biomarkers, Deep Learning, Breast cancer, Humans, skin and connective tissue diseases, neoplasms, Finland, In Situ Hybridization, Proportional Hazards Models, Cancer och onkologi, Gene Amplification, Middle Aged, Trastuzumab, Prognosis, Treatment Outcome, ROC Curve, Cancer and Oncology, Medicine, Female, Biomarkers

وصف الملف: application/pdf; fulltext

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f62cbfe26cee97bcf4f5263f58e2dccb
http://hdl.handle.net/10138/327960